EdgarLookup

Xeris Biopharma Holdings, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Xeris Biopharma Holdings, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q1 2022 Mar 31, 2022 $22.07M May 11, 2022
Q1 2022 Mar 31, 2021 $8.20M May 11, 2022

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $74.38M Nov 6, 2025
Q2 2025 Jun 30, 2025 $71.54M Aug 7, 2025
Q1 2025 Mar 31, 2025 $60.12M May 8, 2025
Q3 2025 Sep 30, 2024 $54.27M Nov 6, 2025
Q2 2025 Jun 30, 2024 $48.07M Aug 7, 2025
Q1 2025 Mar 31, 2024 $40.64M May 8, 2025
Q3 2024 Sep 30, 2023 $48.32M Nov 8, 2024
Q2 2024 Jun 30, 2023 $38.01M Aug 8, 2024
Q3 2023 Sep 30, 2022 $29.73M Nov 9, 2023
Q2 2022 Jun 30, 2022 $25.31M Aug 10, 2022
Q1 2022 Mar 31, 2022 $21.91M May 11, 2022
Q3 2022 Sep 30, 2021 $11.06M Nov 9, 2022
Q2 2022 Jun 30, 2021 $8.91M Aug 10, 2022
Q1 2022 Mar 31, 2021 $8.05M May 11, 2022
Q3 2021 Sep 30, 2020 $9.40M Nov 10, 2021

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $621.0K Nov 6, 2025
Q2 2025 Jun 30, 2025 ($1.93M) Aug 7, 2025
Q3 2025 Jun 30, 2025 ($1.93M) Nov 6, 2025
Q1 2025 Mar 31, 2025 ($9.22M) May 8, 2025
Q2 2025 Mar 31, 2025 ($9.22M) Aug 7, 2025
Q3 2025 Mar 31, 2025 ($9.22M) Nov 6, 2025
Q3 2025 Sep 30, 2024 ($15.74M) Nov 6, 2025
Q3 2025 Jun 30, 2024 ($15.01M) Nov 6, 2025
Q2 2025 Jun 30, 2024 ($15.01M) Aug 7, 2025
Q3 2025 Mar 31, 2024 ($18.98M) Nov 6, 2025
Q1 2025 Mar 31, 2024 ($18.98M) May 8, 2025
Q2 2025 Mar 31, 2024 ($18.98M) Aug 7, 2025
Q3 2024 Sep 30, 2023 ($12.19M) Nov 8, 2024
Q3 2024 Jun 30, 2023 ($19.84M) Nov 8, 2024
Q2 2024 Jun 30, 2023 ($19.84M) Aug 8, 2024
Q2 2024 Mar 31, 2023 ($16.83M) Aug 8, 2024
Q3 2024 Mar 31, 2023 ($16.83M) Nov 8, 2024
Q3 2023 Sep 30, 2022 ($21.83M) Nov 9, 2023
Q2 2022 Jun 30, 2022 ($26.19M) Aug 10, 2022
Q3 2023 Jun 30, 2022 ($26.19M) Nov 9, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $6.73M Nov 6, 2025
Q2 2025 Jun 30, 2025 $4.48M Aug 7, 2025
Q1 2025 Mar 31, 2025 ($3.09M) May 8, 2025
Q3 2025 Sep 30, 2024 ($12.89M) Nov 6, 2025
Q2 2025 Jun 30, 2024 ($8.19M) Aug 7, 2025
Q1 2025 Mar 31, 2024 ($14.25M) May 8, 2025
Q3 2024 Sep 30, 2023 ($4.91M) Nov 8, 2024
Q2 2024 Jun 30, 2023 ($15.98M) Aug 8, 2024
Q3 2023 Sep 30, 2022 ($18.78M) Nov 9, 2023
Q2 2022 Jun 30, 2022 ($18.92M) Aug 10, 2022
Q1 2022 Mar 31, 2022 ($29.07M) May 11, 2022
Q3 2022 Sep 30, 2021 ($24.36M) Nov 9, 2022
Q2 2022 Jun 30, 2021 ($25.79M) Aug 10, 2022
Q1 2022 Mar 31, 2021 ($16.74M) May 11, 2022
Q3 2021 Sep 30, 2020 ($13.74M) Nov 10, 2021